SignalRX Pharmaceuticals, Inc.
1 clinical trials · Sponsor
◉ Watch SignalRX Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma (NCT03059147) | SignalRX Pharmaceuticals, Inc. | 2017-03-27 |
Track SignalRX Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.